The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study Thesedatawill be simultaneously published in the Journal of Clinical Oncologyand highlighted in a late-breaking oral presentationat the 2025American Society of Hematology Annual Meeting and Exposition, and were featured as part of […]

LBA-3:Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile

LBA-6:Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with relapsed/refractory Multiple Myeloma (RRMM): Results of MajesTEC-3 Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal

LBA-5:A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The TRACTION trial When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tranexamic acid (TXA) or a placebo, patients who received TXA needed significantly fewer blood transfusions and saw no increase in potentially life-threatening blood clots (thrombosis) after

LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed

Pariveda recognized as Application Modernization SI Partner of the Year finalist, one of many AWS Partners around the globe that help their customers drive innovation Pariveda, a strategy and technology firm that helps companies make potential possible, is excited to announce it is a finalist for a 2025 Geography and Global AWS Partner Award, recognizing

Pariveda recognized as Social Impact Partner of the Year winner, one of many AWS Partners around the globe that help their customers drive innovation Pariveda is excited to announce it is a recipient of a 2025 Geography and Global AWS Partner Award, recognizing leaders around the globe that are playing key roles in helping their

Strategic hire strengthens focus on growth, margin expansion, and whole-home execution entering 2026 Bed Bath & Beyond, Inc. (NYSE: BBBY) and The Brand House Collective, Inc. (Nasdaq: TBHC) today announced that Nora Gomez has been appointed Chief Merchandising Officer for Bed Bath & Beyond and its family of brands, driving unified product strategy and accountability

Toronto, Ontario–(Newsfile Corp. – December 9, 2025) – Aurum Lake Mining Corporation (TSXV: ARL) (the “Company” or “Aurum“) announces that, further to its news release dated November 21, 2025, regarding the option agreement (the “Option Agreement“) dated November 17, 2025 between the Company and Lipari Mining Ltd. for the exclusive option to earn a 100%

Menlo Ventures' 2025 State of Generative AI Report: Enterprise Investment Hit $37B in 2025, Tripling in One Year AI Applications are the Fastest-Growing Software Category in History, Capturing 6% of the Market in Just Three Years GlobeNewswire December 09, 2025 MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) — Menlo Ventures, a leading venture capital